Urothelial Carcinoma Diagnostics Market by Product (Reagent and Kits, Instruments)
Industry: Healthcare
Published Date: February-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 245
Report ID: PMRREP14128
The Global revenue from the Urothelial Carcinoma Diagnostics Market was about US$ 1.4 Billion in 2022, with the global market expected to grow at a CAGR of 10.9% to reach a valuation of around US$ 4.3 Billion by the end of 2033.
|
Market Size (2023) |
US$ 1.5 Billion |
|
Projected Market Value (2033) |
US$ 4.3 Billion |
|
Global Market Growth Rate (2023 to 2033) |
10.9% CAGR |
|
Market Share of Top 5 Countries |
55.7% |
As assessed by Persistence Market Research, reagents and kits held a market share of around 72.1% in the global market, in 2022. Overall, urothelial carcinoma diagnostics market sales account for approximately 1.8% of revenue share in the global clinical diagnostics market, which was valued at around US$ 74.3 Billion in 2022.
The global market recorded a historic CAGR of 9.6% in the last 7 years from 2015 to 2022. Urothelial carcinoma is a condition where the bladder lining's urothelial cells alter and grow abnormally, eventually forming a mass known as a tumour. The most typical kind of bladder cancer is this one. Tumors in the ureter, urethra, and renal pelvis are also rather common in people with bladder cancer.
An issue arises when bladder tumours spread to deeper bladder layers and become difficult to treat. Blood in the urine, pain, irritation in the bladder, changes in urination patterns, edema, night sweats, weight loss, and fever are among the common signs of urothelial cancer.
Enhanced diagnosis of diverse cancer patients is made possible by better understanding of certain cancer biomarkers, which is fuelling potential growth for diagnostic companies.
In situ hybridization, biopsy, and cystoscopy are some of the most modern diagnostics utilised for the detection and progression of urothelial carcinoma. The identification of potential cancer biomarkers has increased because of technical advancements in the field of biotechnology.
The global market is likely to show high growth over the coming years at a CAGR of 10.9% and reach a global market size of US$ 4.3 Billion by 2033.
“Increased Awareness of Early Urothelial Cancer Screening.”
By receiving a late diagnosis of a malignancy with a strong tendency for metastasis, the relatively high mortality rate associated with urothelial carcinoma can be addressed. If discovered in its early stages, the benign tumour can be substantially eliminated permanently with surgical interlineation, but if it has progressed to other organs, the prognosis for urothelial carcinoma is dismal, with an estimated average survival time of 6–8 months.
A favourable environment for market expansion is anticipated to be created in the near future by rising biomedical research using clinical oncology molecular diagnosis. Recently, cancer biomarkers and immunotherapies have been developed using clinical oncology molecular diagnostic tests. As a result, the market for urothelial carcinoma diagnostics is anticipated to rise due to the rising incidence of cancer.
There has been a lot of interest in clinical molecular diagnostics for cancer in recent years. In order to increase urothelial cancer screening programmes with the aid of the government, numerous clinical development initiatives are being implemented in a number of nations. As a result, the patient with urothelial carcinoma receives early diagnosis and screening.
In order to capture the largest portion of the industry and increase their footprint in the untapped market, the top firms are also developing diagnostic companions in numerous areas with high prevalence rates.
“Lack of Skilled Professionals.”
One significant issue that is anticipated to impede the growth of the market for urothelial carcinoma diagnostics is the lack of competent laboratory personnel. In addition, diagnostic laboratories use cutting-edge technology and automate operations; their ability to expand is constrained by a dearth of qualified personnel who are conversant in molecular techniques. The number of new students graduating from clinical laboratory programs is continually falling, which is impeding market expansion even though the demand for medical laboratory experts is rising.
The testing, identification, and implementation of biomarkers in any molecular diagnostic are issues connected with the discovery of biomarkers that are anticipated to impede the market's expansion for urothelial carcinoma diagnostics.
In order to identify and evaluate biomarkers, there are a number of difficulties related to clone evolution and tumor heterogeneity that must be overcome. Although comprehensive molecular, including metabolomics and proteomics, could aid in the discovery of new predictive biomarkers, their implementation in routine clinical practice has been constrained by critical errors of data reliability between multiple platforms and analogous difficulties of analytical validation.
Why is the United States Market Booming?
“Increasing Prevalence of Bladder Cancer”
The United States accounted for around 86.9% market share in the North America market in 2022. The regional dominance is attributed to growing research and development efforts and a developed healthcare system. The existence of numerous biologics and biopharmaceutical firms is another factor that has contributed to the urothelial carcinoma diagnostics market's size and stellar growth.
Therefore, the need for bladder cancer detection and treatment is anticipated to rise as its prevalence rises, supporting the market's expansion.
Will the Germany Be a Lucrative Market for Urothelial Carcinoma Diagnostics?
“Rise in Awareness of Bladder Cancer”
The Germany market held around 30.7% market share of the Europe market in 2022. The primary factor influencing the market in the region is the rising prevalence of bladder cancer.
The regional market is expanding as a result of rising awareness of the disease and its treatments. Other factors influencing the expansion of the market under study include rising knowledge of bladder disorders, the medicines that are available, and advancements in the creation of new drugs.
How is China Emerging as a Prominent Market?
“Increasing Product Approvals”
China held a market share of about 46.7% of the East Asia market in 2022. The rising incidence of bladder cancer and the advent of new diagnostic and therapeutic techniques are to blame for the regional domination.
Which Product is Driving Demand within the Global Market?
“Specificity of Some Reagents and Kits”
The reagents and kits segment held around 72.1% share of the total market in 2022. Today, it is understood that changes in a number of cellular functions cause urothelial cancer. The use of molecular testing to accurately detect the disease's presence, forecast the behavior of specific tumors, and recommend prospective targeted therapies will be crucial in the care of bladder cancer patients in the future. This specificity of reagents and kits are responsible for segment growth.
Which Test is Widely Adopted for the Production of Urothelial Carcinoma Diagnostics?
“Technological Advancements”
Molecular diagnostic tests held around 43.8% share of the total market in 2022. Early urological cancer identification is essential for effective patient management and treatment. A key advancement would be the development of molecular assays that can reliably identify disease or that can supplement existing methods of evaluation.
The use of such molecular assays on non-invasively obtained body fluids would ideally allow for the identification of at-risk patients as well as asymptomatic screening, disease recurrence tracking, and treatment response monitoring. These objectives are coming into focus because of the development of advanced proteomics and genomics technologies and the related bioinformatics field. These affirmatory factors are responsible for segment growth.
Which End User Propels the Global Sales in the Market?
“Increasing Hospital Facilities Globally”
The hospitals segment held a share of about 46.3% in 2022, within the global market. The growth of hospitals around the world is to blame for the segment's domination. For instance, as per the Organization for Economic Co-operation and Development data, there were around total 6,090 hospitals in the United States, in 2019.
Also, medical tourism has increased on a global scale. With a growth in medical tourism, hospitals should offer higher-quality healthcare services. The aforementioned causes are anticipated to cause the hospitals segment to grow significantly during the projection period.
The market for diagnostics, therapies, and treatments for bladder cancer has a few significant players and is moderately competitive. F. Hoffmann-La Roche Ltd., Novartis, and Pfizer are the principal players on the market. To increase their market shares, the companies now operating in the industry concentrate on new product developments, business expansions, the discovery of new markets, and advancements in their core competencies.
Some key instances of development include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the urothelial carcinoma diagnostics market, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2033 |
|
Historical Data Available for |
2015 to 2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product:
Test:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 1.4 Billion in 2022.
The global market is estimated to reach around US$ 1.5 Billion in 2023.
The global market expected to be valued at around US$ 4.3 Billion by the end of 2033.
Sales of the market are set to witness growth at a CAGR of 10.9% between 2023 and 2033.
Demand for the global market increased at a 9.6% CAGR from 2015 – 2022.
The U.S., Germany, China, the U.K., and Canada account for most demand within the market, currently holding around 55.7% market share.
The U.S. accounts for around 86.9% share of the North American market in 2022.
The China market held a share of about 46.7% in the East Asia urothelial carcinoma diagnostics market in 2022.
The Germany market held around 30.7% market share of the Europe market in 2022.
Roche Holding, Illumina, IDL Biotech, Agilent Technologies, Olympus Corporation, Philips Healthcare, Abbott Molecular, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Danaher Corporation (Cepheid) and GE Healthcare are the leading players in the global market.
